AFTER SINGLE ORAL DOSE OF.../SUCROSE ACETATE (14)C-ISOBUTYRATE/ @ A DOSE LEVEL OF 1 MG/KG, HUMAN SUBJECTS ELIMINATED 40-66% OF (14)CO2 IN EXHALED AIR, 15-21% IN URINE, & 10% IN FECES OVER 30 DAYS, & RATS GAVE SIMILAR PATTERN OF ELIMINATION.
/AFTER ORAL ADMIN OF SUCROSE ACETATE (14)C-ISOBUTYRATE/ PARTIALLY ESTERIFIED SUCROSE DERIVATIVES, AS WELL AS TRACES OF SUCROSE PER SE, WERE PRESENT IN URINE; THESE METABOLITES WERE SIMILAR IN MEN & IN RATS BUT SOMEWHAT DIFFERENT IN DOGS.
...SUCROSE ACETATE ISOBUTYRATE IS METABOLIZED SIMILARLY IN RATS & IN MAN, BUT THAT THE DOG PROCESSES THIS SUGAR DERIVATIVE RATHER DIFFERENTLY BOTH WITH REGARD TO DISPOSITION OF THE DOSE & TO THE NATURE OF URINARY EXCRETORY PRODUCTS.
Dogs and rats received a single dose of (14)C-sucrose acetate isobutyrate ... The rats eliminated 7-10% of the dose in the urine in 30-46 hr and the dogs, 2.8-5.2% of the dose in the urine in 29-30 hr. Size exclusion chromatography of the dog and rat urine showed that (14)C-labelled molecules larger than sucrose were not present to any significant extent. The nature of the metabolites was not determined, although sucrose, glucose and fructose appeared to be absent.
A male /human/ subject was given a single dose of (14)C-sucrose acetate isobutyrate at a dose level of 1.18 mg/kg bw. Samples of urine were collected before dosing and at 0 and 6.2 hr after dosing, and subjected to various chromatographic procedures. Glucose, fructose and the esters of fructose and sucrose were not present in the urine. Two unidentified peaks were considered to be the principal metabolites of sucrose acetate isobutyrate ... .
Twenty subjects (10 males and 10 females) between 18 and 22 years of age ingested a daily dose of sucrose acetate isobutyrate at a level equivalent to 10 mg/kg bw/day for a period of 14 days. The dose was taken as a bolus each morning. The following blood parameters were measured prior to treatment and at days 7 and 18 of the study: aspartate aminotransferase, alanine aminotransferase, serum alkaline phosphatase, serum bilirubin, total protein, albumin, uric acid, blood area nitrogen, erythrocyte sedimentation rate, sodium, potassium, phosphorous, total CO2, cholesterol and glucose. There were no significant differences in any parameters in any individual ... .
In another 14-day study, 12 male and 12 female subjects were divided evenly by sex into 3 groups, receiving a carbonated drink only (controls), or a single daily dose of 7.0 or 20.0 mg sucrose acetate isobutyrate/kg bw/day in a carbonated drink. In addition, four men received 20 mg sucrose acetate isobutyrate/kg bw/day for 1 or 3 days only in a pilot experiment to provide early evaluation of possible alterations in normal hepatic function. The subjects were 21 to 42 years of age. Blood was collected prior to testing and on days 7 and 14 for hematological (platelets, total and differential white blood cells count, erythrocyte sedimentation rate, Hct and hemoglobin) and clinical chemistry (total protein, albumin, A/G ratio, calcium, cholesterol, glucose, blood area nitrogen, uric acid total bilirubin, serum alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, and lactate dehydrogenase) parameters. Standard urinalysis parameters were also recorded at these times. A 45 minute bromosulfophthalein retention test (5 mg/kg bw bromosulfophthalein was also conducte on all subjects prior to treatment and after completion of treatment. Treatment with sucrose acetate isobutyrate did not affect any of these parameters for any individual ... .
Twenty-seven adult subjects, 13 men and 14 women, between the ages of 18 to 55, received sucrose acetate isobutyrate in an aqueous/orange juice emulsion daily for 14 days at a dose of 20 mg/kg bw. In the 7 days prior to treatment, each subject acted as his/her own control by ingesting an orange juice beverage and placebo emulsion. Blood samples were collected from each subject on days -6, 0, 7 and 14 of treatment for measurement of routine hematological and clinical chemistry parameters, including specific indicators of hepatobiliary function (serum alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, gamma-glutamyl transferase, total bilirubin, direct bilirubin, bile acids and serum proteins). No treatment-related changes were detected in any of these parameters over the 14-day dosing period ... .
来源:Hazardous Substances Data Bank (HSDB)
毒理性
非人类毒性摘录
95天亚急性毒性测试表明，犬和鼠对醋酸异丁酸蔗糖酯无反应。
...95-DAY SUB-ACUTE TOXICITY TESTING OF DOGS & RATS WITH SUCROSE ACETATE ISOBUTYRATE SHOWED IT TO BE WITHOUT EFFECT.
Five groups of B6C3F1/Cr1BR mice (10/sex/group) received approx 0, 0.625, 1.25, 2.5 or 5.0 g sucrose acetate isobutyrate/kg bw/day in the diet for 4 wk. Body weights, food consumption and physical exam were recorded at initiation of treatment and weekly during the study. Feeding of sucrose acetate isobutyrate at these doses for 4 wk had no effect on the biological performance of the treated animals. No treatment-related observations were noted at the terminal necropsy ... .
AFTER SINGLE ORAL DOSE OF.../SUCROSE ACETATE (14)C-ISOBUTYRATE/ @ A DOSE-LEVEL OF 1 MG/KG, HUMAN SUBJECTS ELIMINATED 40-66% OF (14)CO2 IN EXHALED AIR, 15-21% IN URINE, & 10% IN FECES OVER 30 DAYS, & RATS GAVE SIMILAR PATTERN OF ELIMINATION, BUT (2) DOGS FED 3 & 5 MG/KG ELIMINATED 53 & 46% IN FECES WITHIN 7 DAYS.
IN RATS, ORALLY ADMIN (14)C SUCROSE ACETATE ISOBUTYRATE WAS HYDROLYZED IN THE GI TRACT PRIOR TO ABSORPTION, & THE SUBSEQUENT FATE OF ADMIN RADIOACTIVITY WAS ANALOGOUS TO THAT OF (14)C SUCROSE. HUMAN STUDIES SHOWED THAT, FOLLOWING A SINGLE ORAL DOSE OR 7 DAILY DOSES OF 1 G SUCROSE ACETATE ISOBUTYRATE (SAIB), THE URINE CONTAINED NO SUCROSE OR PARTIALLY HYDROLYZED SUCROSE ACETATE ISOBUTYRATE. MICROFLORA ASSOCIATED WITH THE LARGE BOWEL EXHIBITED A LIMITED CAPACITY TO HYDROLYZED SUCROSE ACETATE ISOBUTYRATE.
Male albino Holtzman rats, about 250 g, were intubated with (14)C-sucrose acetate isobutyrate of specific activity 0.411 uCi/mg ... in corn oil at dose levels equivalent to 27 or 100 mg/kg bw. The proportion of the admin dose absorbed from the GI tract was greater at the low dose (74-82%) than at the high dose (45-50%). Elimination of 88-90% of the admin dose occurred in 48 hr. The relative proportion of radioactivity eliminated by the various routes varied with the dose. At the high dose level, 54-56% of the absorbed activity was eliminated as CO2 and 26-28% in the urine. At the lower dose, 63-67% of the absorbed activity was eliminated in CO2 and 23-25% in the urine. Four days after the admin of the test cmpd, less than 1% of the admin radioactivity was retained in the GI tract, blood, liver and kidney. Chromatography of extracts of the 24-hr feces of rats showed the presence of sucrose acetate isobutyrate and other metabolites. Most of the radioactivity in urine was in the form of sucrose, although other unidentified substances were also present ... .
... Male albino Holtzman rats weighing approx 250 g received 100 mg/kg bw of (14)C-sucrose acetate isobutyrate (specific activity, 0.38 uCi/mg) in corn oil by gavage. At termination of the study, 3 or 3.5 hr after dosing, 78-84% of the radioactivity was recovered from the GI contents. An additional 7-9% of the radioactivity was recovered from the stomach, intestinal and cecal tissues. Less than 4% of the radioactivity was excreted in the breath, urine and feces within 3-3.5 hr after dosing, indicating that little absorption had taken place. Extracts of the GI contents and organs were found to contain sucrose and partially acylated sucrose esters in addition to unchanged SAIB ... .
Two-coat cosmetic product, its uses, and makeup kit including the product
申请人：——
公开号：US20040228890A1
公开（公告）日：2004-11-18
Disclosed herein is a cosmetic product comprising at least two compositions wherein the first composition comprises a liquid fatty phase and polymer particles dispersed in the liquid fatty phase and the second composition comprises a high molecular weight polymer having a weight-average molecular mass of greater than or equal to 200 000 g/mol; also disclosed are a makeup method and a makeup kit including the product, which may be in the form of a lipstick.
Cosmetic composition comprising at least one polymer particle dispersed in at least one liquid fatty phase and at least one ester of at least acid and at least one polyol ester
申请人：——
公开号：US20040247552A1
公开（公告）日：2004-12-09
The present disclosure, in one embodiment, relates to a cosmetic composition for caring for or making up the skin and/or epidermal derivatives and/or lips, which comprises a physiologically acceptable medium comprising a) at least one liquid fatty phase, b) a dispersion of at least one polymer particle dispersed in the at least one liquid fatty phase, and c) at least one ester of at least one carboxylic acid comprising 1 to 7 carbons and at least one polyol comprising at least 4 hydroxyl groups, the at least one ester having a molecular mass of less than 5,000 g/mol. This composition allows a film to be obtained on the skin, epidermal derivatives or lips which does not undergo transfer, has good staying power and goes on easily.
Two-coat makeup product, its uses, and makeup kit comprising the product
申请人：——
公开号：US20040234564A1
公开（公告）日：2004-11-25
A cosmetic makeup product comprising at least two compositions, the first composition comprising a physiologically acceptable medium and the second composition comprising a mixture of at least one high molecular weight polymer having a weight-average molecular mass of greater than or equal to 200,000 g/mol and at least one low molecular weight non-volatile liquid silicone compound having a weight-average molecular mass of less than 200,000 g/mol, wherein the at least one high molecular weight polymer and the at least one low molecular weight non-volatile liquid silicone compound are present in a proportion such that the dynamic viscosity of the mixture at 25° C., measured with a Mettler RM 180 rotational viscometer, ranges from 0.1 to 120 Pa.s; a makeup method and a makeup kit comprising the cosmetic makeup product. The cosmetic makeup product may, for example, be a lipstick.
Cosmetic composition comprising at least one polymer particle dispersed in at least one liquid fatty phase and at least one compound plasticizing the polymer
申请人：——
公开号：US20040234612A1
公开（公告）日：2004-11-25
The present disclosure relates to a composition, for example, a cosmetic composition for caring for or making up the skin and/or epidermal derivatives and/or lips, which comprises a) at least one liquid fatty phase, b) a dispersion of at least one polymer particle dispersed in the at least one liquid fatty phase, and c) at least one compound chosen from esters of aliphatic and aromatic polycarboxylic acids and aliphatic and aromatic alcohols comprising from 1 to 10 carbon atoms, the at least one compound being present in an amount sufficient to plasticize the at least one polymer particle. The present invention likewise relates to a cosmetic composition for caring for and making up the skin and/or epidermal derivatives and/or lips, which comprises a physiologically acceptable medium comprising a) at least one liquid fatty phase, b) a dispersion of at least one polymer particle dispersed in the at least one liquid fatty phase, and c) at least one compound having a solubility parameter, &dgr;
h
, ranging from 5.5 to 11 (J/cm
3
)
1/2
, the compound being present in an amount sufficient to plasticize the at least one polymer particle.
Cosmetic composition comprising at least one polymer particle dispersed in at least one liquid fatty phase and at least one ester of at least one acid and at least one polyol ester
申请人：Blin Xavier
公开号：US20080107697A1
公开（公告）日：2008-05-08
The present disclosure, in one embodiment, relates to a cosmetic composition for caring for or making up the skin and/or epidermal derivatives and/or lips, which comprises a physiologically acceptable medium comprising a) at least one liquid fatty phase, b) a dispersion of at least one polymer particle dispersed in the at least one liquid fatty phase, and c) at least one ester of at least one carboxylic acid comprising 1 to 7 carbons and at least one polyol comprising at least 4 hydroxyl groups, the at least one ester having a molecular mass of less than 5,000 g/mol. This composition allows a film to be obtained on the skin, epidermal derivatives or lips which does not undergo transfer, has good staying power and goes on easily.
